Ribbon Acquisition Corp Announces Closing of $50 Million Initial Public Offering.

(NASDAQ:RIBBU), New York, New York, Jan. 16, 2025 (GLOBE NEWSWIRE) — Ribbon Acquisition Corp (NASDAQ: RIBBU, the “Company”) today announced the closing of its initial public offering (“IPO”) of 5,000,000 units at an offering price of $10.00 per unit. Each unit consists of one Class A ordinary share and one right to receive one-seventh (1/7) […]

ROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN

(NASDAQ:REGN), NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the “Class Period”). A class

Yahoo Celebrates Marketing Excellence at the 2024 Asia Big Idea Chair Awards

American Express International Inc. crowned Asia Big Idea Chair ChampionBao Dim Sin Seng wins Asia's Best Integrated SolutionVolkswagen Commercial Vehicles awarded Asia Awards Best Branded Content CampaignDebut of Public-Voted Yahoo Best Brand Awards Yahoo hosted the Asia Big Idea Chair Awards 2024 (Yahoo Asia BIC Awards 2024) in Hong Kong and Taiwan, marking 16 years

FTAI ALERT: Bragar Eagel & Squire, P.C. is Investigating FTAI Aviation Ltd. on Behalf of FTAI Stockholders and Encourages Investors to Contact the Firm

(NASDAQ:FTAI), NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against FTAI Aviation Ltd. (“FTAI” or the “Company”) (NASDAQ:FTAI) on behalf of FTAI stockholders. Our investigation concerns whether FTAI has violated the federal securities laws and/or engaged in other unlawful

Stock Music Market , 38% of Growth to Originate from North America, Technavio

The stock music marketsize is estimated to grow by USD 650.4 million from 2024 to 2028, according to Technavio. The market is estimated to grow at a CAGR of 8.09% during the forecast period. https://mma.prnewswire.com/media/2599912/Technavio_global_stock_market.jpg For comprehensive forecast and historic data on regions,market segments, customer landscape, and companies- Click for the snapshot of this report

Fetal Bovine Serum Market to Grow by USD 364.2 Million (2025-2029), Driven by Stem Cell Adoption; AI-Powered Market Evolution – Technavio

Report on how AI is driving market transformation – The global fetal bovine serum marketsize is estimated to grow by USD 364.2 million from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of 6.1% during the forecast period. Rising adoption of stem cell applicationsis driving market growth,with a trend towardsgrowing

New study highlights effectiveness and cost benefits of Myriad™ in lower limb salvage surgeries.

New Zealand headquartered soft tissue regeneration companyAroa Biosurgery recently announced the publication of further strong clinical evidence reinforcing both efficacy and cost benefits of its AROA ECM™ technology when used in high-risk limb salvage surgery. Conducted between May 2022 and April 2023, the single site prospective clinical study included a total of130 complex lower limb

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. – VKTX

NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Viking and certain of its officers and/or directors

HUMA LAWSUIT ALERT: Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, NY / ACCESS Newswire / January 16, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=123335&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

Scroll to Top